NLS Pharmaceutics AG
NASDAQ:NLSP
2.86 (USD) • At close July 1, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2017 Q4 | 2017 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.006 | 0.006 | 0.006 | 0.006 | 0.006 | 0.005 | 0.005 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.006 | -0.006 | -0.006 | -0.006 | -0.006 | -0.005 | -0.005 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 0.271 | 0.002 | 4.384 | 3.433 | 5.544 | 4.057 | 1.863 | 0 | 0.161 | 0.722 | 0.98 | 0 | 0.001 | 3.244 | 1.081 |
| General & Administrative Expenses
| 0.002 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.001 | 0.001 | 0.002 | 0.001 | 0.002 | 0.001 | 1.081 | 0.36 |
| Selling & Marketing Expenses
| 1.775 | 2.724 | 3.157 | 3.353 | 3.135 | 3.253 | 2.672 | 1.217 | 0.92 | 1.246 | 1.245 | 0 | 0 | 0 | 0 |
| SG&A
| 1.776 | 0.003 | 3.16 | 3.356 | 3.138 | 3.256 | 2.675 | 1.218 | 0.921 | 1.248 | 1.247 | 0.002 | 0.001 | 1.081 | 0.36 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 1.21 | 0 | 1.21 | 0 | 0 | 0 | 0 | 0 | 2.883 | -2.883 |
| Operating Expenses
| 2.048 | 0.004 | 7.544 | 6.789 | 8.682 | 7.313 | 4.538 | 1.218 | 1.082 | 1.971 | 2.226 | 0.002 | 0.002 | 7.208 | -1.442 |
| Operating Income
| -2.053 | -0.004 | -7.549 | -6.794 | -8.688 | -7.318 | -4.543 | -1.218 | -1.082 | -1.971 | -2.226 | -0.002 | -0.002 | -4.325 | -1.442 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.018 | -0.302 | -0.063 | -1.061 | 0.047 | -0.025 | -0.061 | -0.412 | -0.151 | -0.061 | -1.189 | -0.001 | -0.001 | -0.668 | -0.223 |
| Income Before Tax
| -2.036 | -0.005 | -7.613 | -7.855 | -8.641 | -7.343 | -4.603 | -1.629 | -1.232 | -2.032 | -3.415 | -0.003 | -0.002 | -4.993 | -1.664 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0 | -0 | -0 | -0 | 0 | -0 | 0 | -0.001 | -0.002 | -0.002 | 0 | 0 | -0.006 | 0 |
| Net Income
| -2.036 | -0.005 | -7.613 | -7.855 | -8.641 | -7.343 | -4.603 | -1.629 | -1.232 | -2.032 | -3.415 | -0.003 | -0.002 | -4.993 | -1.664 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| 0 | -0.141 | -0.2 | -0.29 | -0.54 | -0.5 | -0.42 | -0.34 | -0.11 | -0.18 | -0.31 | -19.32 | -13.57 | -0.41 | -0.16 |
| EPS Diluted
| 0 | -0.141 | -0.2 | -0.29 | -0.54 | -0.5 | -0.42 | -0.34 | -0.11 | -0.18 | -0.31 | -19.32 | -13.57 | -0.41 | -0.16 |
| EBITDA
| -1.943 | -4.409 | -7.544 | -6.789 | -8.682 | -7.338 | -4.538 | -1.484 | -1.144 | -2.032 | -2.591 | 0 | 0 | -4.325 | -1.442 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |